Adverum Biotechnologies Inc (ADVM) Dividend History

Adverum Biotechnologies, publicly traded is a clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, designed as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. On May 12, 2016, Adverum formed as a company after the closing on a transaction with Annapurna Therapeutics. The company announced its common stock will begin trading on Nasdaq under the symbol ADVM as of the open of market.

Last update 12/11/2023